Screening Intervals for Diabetic Retinopathy and Implications for Care

Current Diabetes Reports

Volumn 17, Issue 10, 2017, Pages

  Scanlon, Peter H ^a,b  

^a CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Imaging; Retinal screening; Retinopathy; Screening interval; Sight threatening diabetic retinopathy; Visual loss

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DIABETIC RETINOPATHY; EYE EXAMINATION; HUMAN; LOW RISK POPULATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCREENING TEST; SYSTEMATIC REVIEW; BIOLOGICAL MODEL; COST BENEFIT ANALYSIS; DISEASE EXACERBATION; ECONOMICS; MASS SCREENING; PROCEDURES;

COST-BENEFIT ANALYSIS; DIABETIC RETINOPATHY; DISEASE PROGRESSION; HUMANS; MASS SCREENING; MODELS, BIOLOGICAL; RISK FACTORS;

EID: 85029182331     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-017-0928-6     Document Type: Review

References (58)

1. ONS. How has life expectancy changed over time? 2017. http://visual.ons.gov.uk/how-has-life-expectancy-changed-over-time/. Accessed 08/04/17.
2. Roser M. Rising life expectancy around the world. 2017. https://ourworldindata.org/life-expectancy/. Accessed 08/04/2017.
3. IDF. International Diabetes Federation. IDF Diabetes Atlas. Brussels, Belgium. 2017. http://www.diabetesatlas.org/. Accessed 08/04/17.
4. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865):782–7.
5. Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol. 2012;60(5):428–31.
6. Kristinsson JK, Stefansson E, Jonasson F, Gislason I, Bjornsson S. Screening for eye disease in type 2 diabetes mellitus. Acta Ophthalmol. 1994;72(3):341–6.
7. Kristinsson JK, Stefansson E, Jonasson F, Gislason I, Bjornsson S. Systematic screening for diabetic eye disease in insulin dependent diabetes. Acta Ophthalmol. 1994;72(1):72–8.
8. Agardh E, Agardh CD, Hansson-Lundblad C. The five-year incidence of blindness after introducing a screening programme for early detection of treatable diabetic retinopathy. Diabet Med. 1993;10(6):555–9.
9. Facey K, Cummins E, Macpherson K, Morris A, Reay L, Slattery J. Organisation of Services for Diabetic Retinopathy Screening. Glasgow: Health Technology Board for Scotland 2002.
10. Gillow JT, Gray JA. The National Screening Committee review of diabetic retinopathy screening. Eye. 2001;15(Pt 1):1–2.
11. Thomas RL, Dunstan FD, Luzio SD, Chowdhury SR, North RV, Hale SL et al. Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service. Br J Ophthalmol 2014 1–5. https://doi.org/10.1136/bjophthalmol-2013-304017.
12. Vujosevic S, Midena E. Diabetic retinopathy in Italy: epidemiology data and telemedicine screening programs. J Diabetes Res. 2016;2016:3627465. https://doi.org/10.1155/2016/3627465.
13. Bandurska-Stankiewicz E, Wiatr D. Diabetic blindness significantly reduced in the Warmia and Mazury Region of Poland: Saint Vincent Declaration targets achieved. Eur J Ophthalmol. 2006;16(5):722–7.
14. DiabeticRetinaScreen. Diabetic Retinopathy Screening in Ireland. 2017. https://www.diabeticretinascreen.ie/screening.10.html. Accessed 09/04/2017.
15. Wong TY, Cheung N, Tay WT, Wang JJ, Aung T, Saw SM, et al. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology. 2008;115(11):1869–75.
16. Fransen SR, Leonard-Martin TC, Feuer WJ, Hildebrand PL. Clinical evaluation of patients with diabetic retinopathy: accuracy of the Inoveon diabetic retinopathy-3DT system. Ophthalmology. 2002;109(3):595–601.
17. Silva PS, Cavallerano JD, Tolls D, Omar A, Thakore K, Patel B, et al. Potential efficiency benefits of nonmydriatic ultrawide field retinal imaging in an ocular telehealth diabetic retinopathy program. Diabetes Care. 2014;37(1):50–5. https://doi.org/10.2337/dc13-1292.
18. Murray RB, Metcalf SM, Lewis PM, Mein JK, McAllister IL. Sustaining remote-area programs: retinal camera use by Aboriginal health workers and nurses in a Kimberley partnership. Med J Aust. 2005;182:520–3.
19. Cavallerano JD, Silva PS, Tolson AM, Francis T, Tolls D, Patel B, et al. Imager evaluation of diabetic retinopathy at the time of imaging in a telemedicine program. Diabetes Care. 2012;35(3):482–4.
20. Kirkizlar E, Serban N, Sisson JA, Swann JL, Barnes CS, Williams MD. Evaluation of telemedicine for screening of diabetic retinopathy in the Veterans Health Administration. Ophthalmology. 2013;120(12):2604–10. https://doi.org/10.1016/j.ophtha.2013.06.029.
21. Klein R, Lee K, Gangnon R, Klein B. The 25-year incidence of visual impairment in type 1 diabetes mellitus: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Evid Based Ophthalmol. 2010;12(1):28–9.
22. Pradeepa R, Anjana RM, Unnikrishnan R, Ganesan A, Mohan V, Rema M. Risk factors for microvascular complications of diabetes among south Indian subjects with type 2 diabetes—the Chennai urban rural epidemiology study (CURES) eye study-5. Diabetes Technol Ther. 2010;12(10):755–61. https://doi.org/10.1089/dia.2010.0069.
23. You QS, Xu L, Wang YX, Liang QF, Cui TT, Yang XH, et al. Prevalence of diabetic retinopathy as cause for visual impairment: the Beijing Public Health Care Project. Clin Experiment Ophthalmol. 2013;41(6):608–9. https://doi.org/10.1111/ceo.12053.
24. Schellini SA, De Carvalho GM, Rendeiro FS, Padovani CR, Hirai FE. Prevalence of diabetes and diabetic retinopathy in a Brazilian population. Ophthalmic Epidemiol. 2014;21(1):33–8. https://doi.org/10.3109/09236586.2013.868004.
25. PHE. NHS Screening Programmes in England. 1 April 2015 to 31 March 2016. 2016. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/574713/Screening_in_England_2015_to_2016.pdf. Accessed 04/01/2017 2017.
26. Scanlon PH, Malhotra R, Thomas G, Foy C, Kirkpatrick JN, Lewis-Barned N, et al. The effectiveness of screening for diabetic retinopathy by digital imaging photography and technician ophthalmoscopy. Diabet Med. 2003;20(6):467–74.
27. Spijkerman AM, Dekker JM, Nijpels G, Adriaanse MC, Kostense PJ, Ruwaard D, et al. Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the Hoorn screening study. Diabetes Care. 2003;26(9):2604–8.
28. Bek T, Lund-Andersen H, Hansen AB, Johnsen KB, Sandbaek A, Lauritzen T. The prevalence of diabetic retinopathy in patients with screen-detected type 2 diabetes in Denmark: the ADDITION study. Acta Ophthalmol. 2009;87(3):270–4.
29. Pang C, Jia L, Jiang S, Liu W, Hou X, Zuo Y, et al. Determination of diabetic retinopathy prevalence and associated risk factors in Chinese diabetic and pre-diabetic subjects: Shanghai diabetic complications study. Diabetes Metab Res Rev. 2012;28(3):276–83. https://doi.org/10.1002/dmrr.1307.
30. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–64.
31. Zetoc. The monitoring and search service for global research publications. 2017. http://zetoc.jisc.ac.uk/. Accessed 09/04/2017.
32. Younis N, Broadbent DM, Harding SP, Vora JP. Incidence of sight-threatening retinopathy in Type 1 diabetes in a systematic screening programme. Diabet Med. 2003;20(9):758–65.
33. Younis N, Broadbent DM, Vora JP, Harding SP. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet. 2003;361(9353):195–200.
34. Olafsdottir E, Stefansson E. Biennial eye screening in patients with diabetes without retinopathy: 10-year experience. Br J Ophthalmol. 2007;91(12):1599–601.
35. Misra A, Bachmann MO, Greenwood RH, Jenkins C, Shaw A, Barakat O, et al. Trends in yield and effects of screening intervals during 17 years of a large UK community-based diabetic retinopathy screening programme. Diabet Med. 2009;26(10):1040–7.
36. Soto-Pedre E, Hernaez-Ortega MC, Vazquez JA. Six-year retrospective follow-up study of safe screening intervals for sight-threatening retinopathy in patients with diabetes mellitus. J Diabetes Sci Technol. 2009;3(4):812–8.
37. Agardh E, Tababat-Khani P. Adopting 3-year screening intervals for sight-threatening retinal vascular lesions in type 2 diabetic subjects without retinopathy. Diabetes Care. 2011;34(6):1318–9. https://doi.org/10.2337/dc10-2308.
38. Scanlon PH, Stratton IM, Histed M, Chave SJ, Aldington SJ. The influence of background diabetic retinopathy in the second eye on rates of progression of diabetic retinopathy between 2005 and 2010. Acta Ophthalmol. 2013;91(5):e335–9. https://doi.org/10.1111/aos.12074.
39. Porta M, Maurino M, Severini S, Lamarmora E, Trento M, Sitia E, et al. Clinical characteristics influence screening intervals for diabetic retinopathy. Diabetologia. 2013;56(10):2147–52. https://doi.org/10.1007/s00125-013-2989-7.
40. • Leese GP, Stratton IM, Land M, Bachmann MO, Jones C, Scanlon P, et al. Progression of diabetes retinal status within community screening programs and potential implications for screening intervals. Diabetes Care. 2015;38(3):488–94. https://doi.org/10.2337/dc14-1778. This work was influential in combining data from the UK screening programmes that use different methodologies (e.g. Scotland use one-field staged mydriasis, England and Wales use 2-field mydriatic digital photography and Northern Ireland routine mydriasis over 55 years and staged mydriasis under 55 years).
41. Hughes D, Nair S, Harvey JN. Determining diabetic retinopathy screening interval based on time from no retinopathy to laser therapy. J Med Screen. 2016; https://doi.org/10.1177/0969141316672687.
42. Aspelund T, Thornorisdottir O, Olafsdottir E, Gudmundsdottir A, Einarsdottir AB, Mehlsen J, et al. Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy. Diabetologia. 2011;54(10):2525–32. https://doi.org/10.1007/s00125-011-2257-7.
43. Mehlsen J, Erlandsen M, Poulsen PL, Bek T. Individualized optimization of the screening interval for diabetic retinopathy: a new model. Acta Ophthalmol. 2012;90(2):109–14.
44. Chalk D, Pitt M, Vaidya B, Stein K. Can the retinal screening interval be safely increased to 2 years for type 2 diabetic patients without retinopathy? Diabetes Care. 2012;35(8):1663–8. https://doi.org/10.2337/dc11-2282.
45. •• Stratton IM, Aldington SJ, Taylor DJ, Adler AI, Scanlon PH. A simple risk stratification for time to development of sight-threatening diabetic retinopathy. Diabetes Care. 2013;36(3):580–5. https://doi.org/10.2337/dc12-0625. This was the first report of the method if risk stratification based on two negative screens.
46. Looker HC, Nyangoma SO, Cromie DT, Olson JA, Leese GP, Philip S, et al. Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme. Diabetologia. 2013;56(8):1716–25. https://doi.org/10.1007/s00125-013-2928-7.
47. Day TE, Ravi N, Xian H, Brugh A. Sensitivity of diabetic retinopathy associated vision loss to screening interval in an agent-based/discrete event simulation model. Comput Biol Med. 2014;47:7–12. https://doi.org/10.1016/j.compbiomed.2014.01.007.
48. Lund SH, Aspelund T, Kirby P, Russell G, Einarsson S, Palsson O, et al. Individualised risk assessment for diabetic retinopathy and optimisation of screening intervals: a scientific approach to reducing healthcare costs. Br J Ophthalmol. 2016;100(5):683–7. https://doi.org/10.1136/bjophthalmol-2015-307341.
49. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA. 2000;283(7):889–96.
50. •• Scanlon PH, Aldington SJ, Leal J, Luengo-Fernandez R, Oke J, Sivaprasad S, et al. Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. Health Technol Assess. 2015;19(74):1–116. https://doi.org/10.3310/hta19740. This work provided cost-effectivenss data in different populations.
51. Klein R. Screening interval for retinopathy in type 2 diabetes. Lancet. 2003;361(9353):190–1.
52. Leese GP. Should diabetes retinal screening intervals change? Diabet Med. 2013;30(1):43–5.
53. Yeo S, Edwards R, Luzio S, Charles J, Thomas R, Peters J, et al. Diabetic retinopathy screening: perspectives of people with diabetes, screening intervals and costs of attending screening. Diabet Med. 2012;29(7):878–85.
54. Yeo S, Edwards R, Fargher E, Luzio S, Thomas R, Owens D. Preferences of people with diabetes for diabetic retinopathy screening: a discrete choice experiment. Diabet Med. 2012;29(7):869–77.
55. Echouffo-Tcheugui JB, Ali MK, Roglic G, Hayward RA, Venkat Narayan KM. Screening intervals for diabetic retinopathy and incidence of visual loss: a systematic review. Diabet Med. 2013;
56. Taylor-Phillips S, Mistry H, Leslie R, Todkill D, Tsertsvadze A, Connock M, et al. Extending the diabetic retinopathy screening interval beyond 1 year: systematic review. Br J Ophthalmol. 2016;100(1):105–14. https://doi.org/10.1136/bjophthalmol-2014-305938.
57. NSC. The UK NSC recommendations on Diabetic Retinopathy screening in adults. 2016. https://legacyscreening.phe.org.uk/diabeticretinopathy. Accessed 10/04/2016.
58. Appelbe D, Broadbent D, Mobayen-Rahni M, Eleuteri A, Bennett A, Moitt T, et al. Introducing personalised risk based intervals in screening for diabetic retinopathy: development, implementation and assessment of safety, cost-effectiveness and patient experience (ISDR): a case study in the use of automated systems in trials. Trials. 2015;16(Suppl 2):O59. 3rd International Clinical Trials Methodology Conference, Glasgow, UK.